Related Experiment Video
Updated: Oct 7, 2025
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
Myeloperoxidase: a new target for the treatment of stroke?
Yun-Chang Wang1, Yu-Bao Lu2, Xiao-Lan Huang3
1The Second Clinical Medical School, Lanzhou University; Department of Neurosurgery, Lanzhou University Second Hospital, Lanzhou, Gansu Province; Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Abstract:
Myeloperoxidase is an important inflammatory factor in the myeloid system, primarily expressed in neutrophils and microglia. Myeloperoxidase and its active products participate in the occurrence and development of hemorrhagic and ischemic stroke, including damage to the blood-brain barrier and brain. As a specific inflammatory marker, myeloperoxidase can be used in the evaluation of vascular disease occurrence and development in stroke, and a large amount of experimental and clinical data has indicated that the inhibition or lack of myeloperoxidase has positive impacts on stroke prognosis. Many studies have also shown that there is a correlation between the overexpression of myeloperoxidase and the risk of stroke. The occurrence of stroke not only refers to the first occurrence but also includes recurrence. Therefore, myeloperoxidase is significant for the clinical evaluation and prognosis of stroke. This paper reviews the potential role played by myeloperoxidase in the development of vascular injury and secondary brain injury after stroke and explores the effects of inhibiting myeloperoxidase on stroke prognosis. This paper also analyzes the significance of myeloperoxidase etiology in the occurrence and development of stroke and discusses whether myeloperoxidase can be used as a target for the treatment and prediction of stroke.
Insights
Myeloperoxidase (MPO) is a key inflammatory factor implicated in stroke development and progression. Inhibiting MPO shows promise for improving stroke prognosis and offers potential as a therapeutic target.
Area of Science:
- Neuroscience
- Immunology
- Cardiovascular Research
Background:
- Myeloperoxidase (MPO) is a crucial inflammatory mediator primarily found in neutrophils and microglia.
- MPO and its byproducts are involved in the pathogenesis of both hemorrhagic and ischemic stroke, contributing to blood-brain barrier damage and brain injury.
Purpose of the Study:
- To review the role of MPO in stroke-related vascular and secondary brain injury.
- To explore the impact of MPO inhibition on stroke prognosis.
- To analyze MPO's etiological significance in stroke and its potential as a therapeutic and predictive target.
Main Methods:
- Literature review of experimental and clinical data on myeloperoxidase in stroke.
- Analysis of MPO's role in vascular injury and secondary brain damage.
- Evaluation of MPO inhibition strategies and their effect on stroke outcomes.
Main Results:
- MPO is a significant inflammatory marker in stroke evaluation.
- Evidence suggests MPO inhibition or deficiency positively influences stroke prognosis.
- Overexpression of MPO correlates with increased stroke risk, including recurrence.
Conclusions:
- Myeloperoxidase plays a critical role in the development and progression of stroke.
- Targeting MPO presents a promising avenue for stroke treatment and prediction.
- Further research into MPO inhibition could significantly improve clinical outcomes for stroke patients.
![PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F57243.jpg&w=3840&q=50)